Myelodysplastic Syndromes (MDS): Recent Updates and Evolving Treatment Paradigms - Episode 5
Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.